Compass Therapeutics vs Cardiff Oncology
CMPX and CRDF side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CMPX and CRDF compare
Compass Therapeutics is the larger company, worth 1.7 times as much as Cardiff Oncology ($109M against $65.8M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CMPX | CRDF |
|---|---|---|
| Size and price | ||
| Market cap | $109M | $65.8M |
| Share price | $0.607 | $0.846 |
| Change, 1 year | −87.4% | −60.3% |
| Change, 5 years | −81.2% | −84.9% |
| Beta (5Y) | 2.20 | 2.50 |
| Employees | 39 | 31 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 130× |
| P/B | 0.7× (better) | 2.5× |
| FCF yield | −51.6% | – |
| Growth | ||
| Revenue growth (TTM) | – | −7.0% |
| Revenue growth, 5Y average | – | 10.1% |
| Profitability | ||
| Operating margin | – | −8320% |
| Net margin | – | −7884% |
| Return on equity | −56.7% (better) | −94.1% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 11.22 (better) | 3.30 |
| Altman Z-score | −1.14 (better) | −16.20 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.0% | 24.2% |
| Held by insiders | 26.3% | 4.9% |
| Insider net buying, 12 months | $96.8K | $1.1M (better) |
| Short interest, % of float | 30.7% | 16.6% |
Go deeper
- CMPX stock overview
- CMPX income statement
- CMPX valuation and score
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.